IsoRay, Inc. (NYSE:ISR) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 4,572,738 shares, a drop of 5.5% from the December 31st total of 4,838,632 shares, Marketbeat.com reports. Currently, 8.4% of the company’s shares are sold short. Based on an average trading volume of 485,139 shares, the short-interest ratio is presently 9.4 days.

In other news, CEO Dwight William Babcock purchased 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were acquired at an average price of $1.27 per share, for a total transaction of $31,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 326,402 shares in the company, valued at $414,530.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Separately, Maxim Group decreased their price target on IsoRay from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, November 10th.

IsoRay (NYSE:ISR) opened at 0.7001 on Thursday. The company’s market cap is $38.51 million. The company has a 50-day moving average price of $0.86 and a 200 day moving average price of $1.26. IsoRay has a 12-month low of $0.55 and a 12-month high of $3.79.

IsoRay (NYSE:ISR) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by $0.01. The company earned $1.46 million during the quarter, compared to analyst estimates of $1.04 million. On average, analysts forecast that IsoRay will post $0.08 EPS for the current fiscal year.

IsoRay, Inc. develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in treatment for all solid tumors using Cesium-131. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (NYSE:ISR). The Company’s product candidate is Proxcelan Cesium-131. The Company markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; brain cancer; lung cancer; head and neck cancers; gynecological cancer: pelvic/abdominal cancer; colorectal cancer, and ocular melanoma. It also markets the GliaSite RTS for the treatment of brain cancer, such as primary and recurrent gliomas and metastic brain tumors. GliaSite RTS is a cleared balloon catheter device. The components included in the GliaSite RTS are the GliaSite Catheter Tray, GliaSite Access Tray, Iotrex Solidifier and either Iotrex or Cesitrex as the radiotherapy solution.

12 Month Chart for NYSE:ISR

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for IsoRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.